These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
622 related articles for article (PubMed ID: 26630874)
1. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma. Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874 [TBL] [Abstract][Full Text] [Related]
2. Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria. Albano D; Bosio G; Re A; Pagani C; Giubbini R; Bertagna F Leuk Lymphoma; 2019 Feb; 60(2):326-333. PubMed ID: 29966473 [TBL] [Abstract][Full Text] [Related]
3. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438 [TBL] [Abstract][Full Text] [Related]
4. [Value of Pretherapeutic Ding CY; Liu HY; Guo Z; Li TN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):438-443. PubMed ID: 28446289 [TBL] [Abstract][Full Text] [Related]
5. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type. Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633 [TBL] [Abstract][Full Text] [Related]
6. Dynamic evaluation of the prognostic value of Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350 [TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma. Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643 [TBL] [Abstract][Full Text] [Related]
9. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma. Riad R; Omar W; Sidhom I; Zamzam M; Zaky I; Hafez M; Abdel-Dayem HM Nucl Med Commun; 2010 Mar; 31(3):232-8. PubMed ID: 20032800 [TBL] [Abstract][Full Text] [Related]
10. Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma. Albano D; Re A; Tucci A; Giubbini R; Bertagna F Ann Nucl Med; 2019 Apr; 33(4):280-287. PubMed ID: 30788775 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma. Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008 [TBL] [Abstract][Full Text] [Related]
13. Complete Metabolic Response on Interim Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. Itti E; Lin C; Dupuis J; Paone G; Capacchione D; Rahmouni A; Haioun C; Meignan M J Nucl Med; 2009 Apr; 50(4):527-33. PubMed ID: 19289424 [TBL] [Abstract][Full Text] [Related]
15. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival. Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985 [TBL] [Abstract][Full Text] [Related]
16. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD. Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197 [TBL] [Abstract][Full Text] [Related]
18. Nomograms based on SUVmax of Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476 [TBL] [Abstract][Full Text] [Related]
19. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Huang H; Xiao F; Han X; Zhong L; Zhong H; Xu L; Zhu J; Ni B; Liu J; Fang Y; Zhang M; Shen L; Wang T; Liu J; Shi Y; Chen Y; Zheng L; Liu Q; Chen F; Wang J Nucl Med Commun; 2016 Jul; 37(7):689-98. PubMed ID: 27244584 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. Kwon SH; Kang DR; Kim J; Yoon JK; Lee SJ; Jeong SH; Lee HW; An YS Clin Radiol; 2016 Mar; 71(3):280-6. PubMed ID: 26732889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]